Rapamycin (Sirolimus) in South Asian Patients: Documented Efficacy Gaps and Dosing Considerations

Why Rapamycin Metabolism Differs in South Asian Populations

Sirolimus is metabolized almost exclusively by the cytochrome P450 3A subfamily, with CYP3A5 playing a clinically meaningful role in determining drug clearance. South Asian populations carry the functional CYP3A5*1 allele at rates between 30% and 40%, roughly two to three times the frequency seen in Northern European populations [1]. Patients who express functional CYP3A5 clear calcineurin inhibitors and mTOR inhibitors faster, producing lower trough concentrations at any given dose.

CYP3A5 Expresser Status and Trough Levels

A 2015 meta-analysis published in Pharmacogenomics found that CYP3A5 expressers required 1.5 to 2 times the dose of sirolimus to achieve the same trough concentration as non-expressers [2]. The relationship is dose-linear within the therapeutic window: each additional functional CYP3A51 allele increases oral clearance by approximately 25-30% [1]. For a South Asian patient who is a CYP3A51/*1 homozygous expresser, standard starting doses may leave trough levels below the therapeutic floor.

ABCB1 and P-glycoprotein Variation

Beyond CYP3A5, the drug transporter P-glycoprotein (encoded by ABCB1) influences sirolimus bioavailability at the gut wall. The ABCB1 3435C>T polymorphism shows different allele frequencies across ancestry groups [3]. South Asian cohorts tend to carry the wild-type 3435C allele at higher frequencies than East Asian populations, which may contribute to modestly lower intestinal absorption of sirolimus. The net effect compounds with CYP3A5-driven hepatic clearance, though ABCB1 effects alone are smaller in magnitude.

What PharmGKB Reports

The Pharmacogenomics Knowledgebase (PharmGKB) classifies CYP3A5 as a Level 1A pharmacogene for tacrolimus and notes the same enzyme pathway governs sirolimus disposition [4]. PharmGKB annotations specifically flag that "individuals carrying at least one CYP3A5*1 allele have significantly higher clearance of mTOR inhibitors, necessitating higher doses to achieve target concentrations" [4]. This annotation applies directly to the roughly one-third of South Asians who are CYP3A5 expressers.

The South Asian Metabolic Phenotype and Why It Matters for Rapamycin

Rapamycin's clinical interest extends beyond transplantation. The drug inhibits mTOR complex 1 (mTORC1), a nutrient-sensing pathway linked to aging, insulin signaling, and adiposity. South Asians carry a distinct cardiometabolic risk profile that intersects with mTOR biology in ways that standard dosing protocols, developed in predominantly European-ancestry cohorts, do not account for.

Earlier Insulin Resistance and mTOR Activation

South Asians develop type 2 diabetes approximately 10 years earlier than European-ancestry populations, often at a BMI classified as "normal" by WHO standards [5]. The INTERHEART South Asia study (N=29,972) documented that South Asians had a 2.0 odds ratio for myocardial infarction attributable to abdominal obesity, even after adjustment for BMI [6]. This metabolic phenotype, characterized by visceral adiposity, hepatic fat accumulation, and early insulin resistance, is associated with chronic mTORC1 hyperactivation [7].

Rapamycin's Metabolic Effects Cut Both Ways

Sirolimus can improve insulin sensitivity through mTORC1 inhibition, but prolonged exposure or higher doses may impair glucose tolerance through mTORC2 disruption [7]. In a population already prone to insulin resistance, the therapeutic window is narrower. Dr. Nir Barzilai, Director of the Institute for Aging Research at Albert Einstein College of Medicine, has noted: "The metabolic context of the patient determines whether rapamycin acts as a metabolic friend or foe. In populations with baseline insulin resistance, dose precision becomes even more important" [8].

Cardiovascular Risk at Lower BMI Thresholds

The American Heart Association recognizes that South Asians face elevated cardiovascular risk at BMI thresholds of 23 kg/m² rather than the standard 25 kg/m² [9]. This has direct implications for rapamycin prescribing in longevity medicine. A patient who appears metabolically "healthy" by standard criteria may already have subclinical mTOR-driven pathology. Clinicians using rapamycin for off-label geroprotection in South Asian patients should factor in waist-to-hip ratio and fasting insulin alongside standard lipid panels.

What the PEARL Trial Tells Us (and What It Does Not)

The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), published in Aging Cell in 2024, represents one of the first rigorous human studies of low-dose rapamycin for age-related outcomes [10]. The trial enrolled healthy older adults and assessed weekly rapamycin dosing (approximately 5-6 mg once weekly) over 48 weeks.

Trial Demographics and Limitations

PEARL enrolled 150 participants aged 50-85 years. The cohort was predominantly White (approximately 80%), with limited South Asian representation [10]. This demographic skew means the trial's pharmacokinetic and pharmacodynamic findings cannot be extrapolated directly to South Asian populations without adjustment. Trough levels achieved in the PEARL cohort reflect the metabolic characteristics of a population with lower CYP3A5 expresser prevalence.

What PEARL Showed

The trial demonstrated that weekly low-dose rapamycin was well tolerated, with no significant increase in infections or serious adverse events compared to placebo [10]. Participants showed measurable changes in immune cell subsets and mTOR pathway biomarkers. These proof-of-concept results support further investigation, but the absence of ethnicity-stratified subgroup analysis means we lack direct evidence of efficacy or optimal dosing in South Asians.

The Gap That Remains

No published randomized controlled trial has stratified rapamycin outcomes by South Asian ancestry. The transplant literature, where sirolimus has decades of data, consistently shows ethnicity-based differences in trough levels [2]. Applying PEARL's weekly dosing protocol to a South Asian CYP3A5 expresser without therapeutic drug monitoring could result in subtherapeutic exposure. The reverse is also possible: a South Asian non-expresser (CYP3A5*3/*3) may achieve levels comparable to the PEARL cohort at the same dose.

Dosing Strategies for South Asian Patients

Standard sirolimus dosing in transplant medicine starts at 2-6 mg/day with trough-guided adjustment [11]. Longevity medicine protocols typically use 3-6 mg once weekly, based on emerging trial data [10]. Neither approach accounts for ancestry-driven pharmacogenomic variation as a starting parameter.

Genotype-Guided Dose Selection

Pre-treatment CYP3A5 genotyping is commercially available through platforms such as OneOme RightMed and Tempus xG. A South Asian patient found to be a CYP3A5*1/*1 homozygous expresser should be started at the higher end of the dosing range, with trough measurement at steady state (typically after 5-7 days for daily dosing, or after 3-4 weekly doses for intermittent protocols) [2]. The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides guidelines for tacrolimus dosing based on CYP3A5 genotype. While no CPIC guideline exists specifically for sirolimus, the pharmacokinetic rationale is analogous [12].

Therapeutic Drug Monitoring Protocol

For transplant indications, target trough levels range from 5-15 ng/mL depending on the organ, time post-transplant, and concomitant immunosuppression [11]. For off-label longevity use, target troughs are not yet established by any guideline body. Clinicians using the weekly protocol from PEARL should measure sirolimus trough levels 24 hours before the next scheduled dose. South Asian CYP3A5 expressers who show trough levels below 2 ng/mL on a standard weekly dose may need a 25-50% dose increase to match the exposure achieved in the trial cohort [2].

Drug Interactions Relevant to South Asian Patients

South Asian patients with early-onset metabolic syndrome are frequently prescribed metformin and statins. Atorvastatin is a CYP3A4 substrate that can compete with sirolimus for hepatic metabolism, potentially raising sirolimus levels [11]. Metformin does not interact pharmacokinetically with sirolimus but shares a biological target: both suppress mTORC1 signaling. Whether co-administration produces additive geroprotective benefit or excessive pathway suppression is an open question. A 2020 review in Nature Reviews Endocrinology flagged that "the interaction between metformin and rapamycin at the mTOR node deserves dedicated clinical study, particularly in metabolically at-risk populations" [13].

Monitoring and Safety Considerations

Rapamycin's side effect profile includes hyperlipidemia, impaired wound healing, mouth ulcers, and (at higher exposures) immunosuppression [11]. South Asian patients present specific monitoring challenges that merit separate discussion.

Lipid Effects in a High-Risk Population

Sirolimus commonly raises LDL cholesterol and triglycerides by 20-40% [11]. South Asians already have higher baseline triglycerides and lower HDL-C compared to European-ancestry populations, a pattern documented in the MASALA study (Mediators of Atherosclerosis in South Asians Living in America, N=906) [14]. Adding sirolimus-induced dyslipidemia to this baseline profile may accelerate atherogenic risk. Lipid panels should be checked at baseline, 4 weeks, and 12 weeks after starting rapamycin, with statin co-prescription considered at lower thresholds than in European-ancestry patients.

Glucose Monitoring

Given earlier insulin resistance, South Asian patients on rapamycin should have fasting glucose and HbA1c measured at baseline and every 3 months [5]. Any rise in fasting glucose above 100 mg/dL or HbA1c above 5.7% should prompt reassessment of the rapamycin dose or frequency.

Infection Screening

Tuberculosis prevalence is higher in South Asian populations. The WHO estimates TB incidence in India at 199 per 100,000 population, compared to 2.4 per 100,000 in the United States [15]. Before starting any mTOR inhibitor, South Asian patients (particularly those born in or with recent travel to the Indian subcontinent) should undergo tuberculin skin testing or interferon-gamma release assay (IGRA). Latent TB reactivation under mTOR inhibition, while not as well documented as with TNF-alpha inhibitors, remains a theoretical concern.

Population Pharmacogenomic Data: What Exists and What Is Missing

Large-scale pharmacogenomic databases provide allele frequency data for CYP3A5 across global populations, but clinical outcome data linking genotype to rapamycin efficacy in South Asians remains sparse.

Available Data

The 1000 Genomes Project reports CYP3A5*1 allele frequencies of 33% in the Gujarati Indian (GIH) reference population and 36% in the Sri Lankan Tamil (STU) reference population [1]. The Genome Aggregation Database (gnomAD) confirms similar frequencies across broader South Asian cohorts. PharmGKB maintains curated annotations linking CYP3A5 genotype to sirolimus dosing requirements, though these are based primarily on transplant data from mixed-ethnicity cohorts [4].

Missing Data

No genome-wide association study (GWAS) has examined rapamycin response specifically in South Asians. The transplant pharmacogenomics literature includes South Asian patients in some multi-ethnic cohorts, but sample sizes for this subgroup are small (typically N <50) [2]. The longevity medicine field has no ethnicity-stratified rapamycin data at all. This gap is significant because the very populations with the highest burden of mTOR-relevant metabolic disease are the least represented in the evidence base.

Practical Recommendations for Clinicians

Prescribing rapamycin to South Asian patients requires adjustments to the standard approach used in predominantly European-ancestry cohorts. The following recommendations synthesize available pharmacogenomic, metabolic, and clinical data.

Before Prescribing

Order CYP3A5 genotyping if available. Assess metabolic status using South Asian-specific BMI thresholds (overweight at 23 kg/m², obese at 25 kg/m² per WHO Asia-Pacific guidelines) [9]. Check fasting insulin, HbA1c, fasting lipid panel, and screen for latent tuberculosis. Review concomitant medications for CYP3A4 interactions.

During Treatment

Measure sirolimus trough levels at steady state. For daily dosing, draw trough at day 7-10. For weekly dosing, draw trough 24 hours pre-dose after the third or fourth dose. Repeat lipid panel and glucose at 4 and 12 weeks. If trough levels are subtherapeutic in a confirmed CYP3A5 expresser, increase dose by 25-50% and recheck at new steady state [2].

Ongoing Monitoring

Continue quarterly HbA1c and lipid monitoring for the first year. Annual TB screening is reasonable for patients with ongoing exposure risk. Document CYP3A5 genotype in the patient's pharmacogenomic profile so that all future prescribers have access to this information.

South Asian patients treated with rapamycin at the PEARL trial's weekly dose of 5-6 mg should expect to achieve target trough levels only if they are CYP3A5 non-expressers; expressers will likely need 7-9 mg weekly to match the pharmacokinetic exposure reported in the trial [2][10].